Great News
Relay, Fio begin ops for Fionet COVID tracking platform
2020-08-26 19:37 ET - News Release
Mr. Yoav Raiter reports
RELAY MEDICAL AND FIO CORPORATION LAUNCH MOBILE COVID-19 TESTING AND TRACKING PLATFORM
Relay Medical Corp. and Fio Corp. have commenced operations of the Fionet rapid response group (FRR) to bring a new COVID-19 mobile testing and tracking platform to market.
FRR is now in negotiation for trial deployments with several potential partners.
Relay and Fio previously announced a joint venture on Aug. 19, 2020, to rapidly launch and deploy a new COVID-19 testing, data collection and reporting solution. The JV operates under the name Fionet Rapid Response Group and is headquartered in Toronto, Canada.
"Community-based testing and real-time tracking is indispensable for combating pandemics like COVID-19. Fionet has already made this happen in the most challenging epidemic regions on the planet, and we are now preparing for imminent deployment of our platform with several partners to combat COVID-19 at home and abroad," said Dr. Michael Greenberg, chief executive officer of Fionet Rapid Response Group.
Fionet is a mobile testing and tracking platform specifically developed for controlled, rapid response to pandemics. The platform combines hand-held devices linked to on-line artificial-intelligence-powered cloud, automating front line testing and capturing test results for tracking. Fionet's rugged, mobile devices are compatible with multiple third party antigen and antibody COVID-19 rapid diagnostic tests (RDTs), which create sourcing flexibility for RDTs, which are of limited supply and continuously evolving. Fionet also connects with molecular testing devices such as PCRs.
Fio's cloud platform delivers real-time, actionable intelligence for supervisors and public health officials to manage responses and resources to new levels of precision and promptness. Data and insights are delivered to dashboards, information technology systems and public health databases for rapid, secure and data-informed responses.
Flexible and customizable, Fionet enables diagnostic testing in any community-based setting to support a variety of return-to-work use cases. Testing can be expanded beyond the few overburdened medical centres to small clinics, pharmacies, workplaces, airports, nursing homes and schools, and performed at hospital-grade accuracy, in higher volume, at faster speed and by less skilled front line workers.
Fionet has proved positive impact on one million patients with infectious diseases in over a dozen countries and four continents. Fio managed testing programs for high-consequence diseases such as malaria, HIV, dengue and ebola in partnership with world-class organizations, including World Health Organization, Bill & Melinda Gates Foundation, Ministry of Health of Democratic Republic of Congo (DRC) and Republic of Kenya Ministry of Health.
"The many transformational benefits delivered by Fionet have been validated and documented in several dozen scientific and medical journals. Fionet has successfully reduced testing errors by 23 per cent, achieves 99.5-per-cent (1) diagnostic accuracy rate compared to expert lab techs and provides significant economic efficiencies," said Yoav Raiter, chief executive officer, Relay Medical.
(1) Noble et al., Continuous quality monitoring in the field: an evaluation of the performance of the Fio Deki Reader for rapid HIV testing in South Africa. BMC Infectious Diseases (2020) 20 to 320.
The companies are not making any express or implied claims that their product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 coronavirus) at this time.
About Relay Medical Corp.
Relay Medical is a medtech innovation company headquartered in Toronto, Canada, focused on the development of novel technologies in the diagnostics and artificial intelligence data science sectors.
We seek Safe Harbor.
© 2020 Canjex Publishing Ltd. All rights reserved.